Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2024 - 2025)

Historic Non-Current Deffered Revenue for Aclaris Therapeutics (ACRS) over the last 2 years, with Q3 2025 value amounting to $17.5 million.

  • Aclaris Therapeutics' Non-Current Deffered Revenue fell 1742.05% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 1742.05%. This contributed to the annual value of $20.0 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Aclaris Therapeutics' Non-Current Deffered Revenue stood at $17.5 million, which was down 1742.05% from $18.2 million recorded in Q2 2025.
  • Aclaris Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $21.2 million during Q3 2024, with a 5-year trough of $17.5 million in Q3 2025.